GLP-1 & Metabolic
Metabolic health, appetite regulation, and modern weight management.
116 articles in GLP-1 & Metabolic · page 10 of 10
GLP-1s and Muscle Loss: Protecting Lean Mass
DEXA substudies show roughly a quarter to a third of the weight lost is lean mass. What training and protein intake can do.
Read →Managing GLP-1 Nausea: What the Evidence Suggests
Most GLP-1 nausea is dose- and titration-related, usually mild, and fades with time. What the evidence suggests actually helps, and when.
Read →What Happens When You Stop a GLP-1?
Trials show most people regain a large share of lost weight after stopping a GLP-1. What the data says, and what predicts it.
Read →Retatrutide: The Triple Agonist on the Horizon
Phase 2 data put retatrutide at 24.2% weight loss in 48 weeks — the largest yet. Why that deserves both attention and restraint.
Read →Oral Semaglutide: Does the Pill Match the Injection?
The Wegovy pill is now FDA-approved. Trial data shows it can match the injection, if the strict dosing rules are followed.
Read →Tirzepatide: How the Dual Agonist Changed the Field
Tirzepatide hit 22.5% average weight loss in SURMOUNT-1 by targeting both GIP and GLP-1 receptors at once. Why that reset the field.
Read →Semaglutide vs Tirzepatide: Comparing the Heavyweights
SURMOUNT-5 gave a direct head-to-head: tirzepatide 20.2% vs semaglutide 13.7% weight loss. What that does and doesn't settle.
Read →Liraglutide: The GLP-1 That Started It All
Before semaglutide there was liraglutide. What the first widely used GLP-1 taught the field, and where it still fits in treatment today.
Read →